vs
Apellis Pharmaceuticals, Inc.（APLS）与Donnelley Financial Solutions, Inc.（DFIN）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Donnelley Financial Solutions, Inc.的1.2倍（$199.9M vs $172.5M），Donnelley Financial Solutions, Inc.净利率更高（3.6% vs -29.5%，领先33.1%），Donnelley Financial Solutions, Inc.同比增速更快（10.4% vs -5.9%），Donnelley Financial Solutions, Inc.自由现金流更多（$47.9M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -7.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
唐nelley金融解决方案（DFIN）是一家总部位于美国伊利诺伊州芝加哥市的金融合规企业，面向资本市场与投资市场的各类企业，提供符合美国监管要求的软件即服务产品、软件赋能服务、印刷业务及合规相关服务，助力客户满足合规要求。
APLS vs DFIN — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $172.5M |
| 净利润 | $-59.0M | $6.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 8.3% |
| 净利率 | -29.5% | 3.6% |
| 营收同比 | -5.9% | 10.4% |
| 净利润同比 | -62.2% | -1.6% |
| 每股收益（稀释后） | $-0.40 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $172.5M | ||
| Q3 25 | $458.6M | $175.3M | ||
| Q2 25 | $178.5M | $218.1M | ||
| Q1 25 | $166.8M | $201.1M | ||
| Q4 24 | $212.5M | $156.3M | ||
| Q3 24 | $196.8M | $179.5M | ||
| Q2 24 | $199.7M | $242.7M | ||
| Q1 24 | $172.3M | $203.4M |
| Q4 25 | $-59.0M | $6.2M | ||
| Q3 25 | $215.7M | $-40.9M | ||
| Q2 25 | $-42.2M | $36.1M | ||
| Q1 25 | $-92.2M | $31.0M | ||
| Q4 24 | $-36.4M | $6.3M | ||
| Q3 24 | $-57.4M | $8.7M | ||
| Q2 24 | $-37.7M | $44.1M | ||
| Q1 24 | $-66.4M | $33.3M |
| Q4 25 | -25.6% | 8.3% | ||
| Q3 25 | 48.7% | 16.1% | ||
| Q2 25 | -18.6% | 24.2% | ||
| Q1 25 | -50.0% | 22.8% | ||
| Q4 24 | -12.3% | 6.0% | ||
| Q3 24 | -24.0% | 10.1% | ||
| Q2 24 | -14.7% | 26.6% | ||
| Q1 24 | -36.0% | 21.9% |
| Q4 25 | -29.5% | 3.6% | ||
| Q3 25 | 47.0% | -23.3% | ||
| Q2 25 | -23.6% | 16.6% | ||
| Q1 25 | -55.3% | 15.4% | ||
| Q4 24 | -17.1% | 4.0% | ||
| Q3 24 | -29.2% | 4.8% | ||
| Q2 24 | -18.9% | 18.2% | ||
| Q1 24 | -38.5% | 16.4% |
| Q4 25 | $-0.40 | $0.31 | ||
| Q3 25 | $1.67 | $-1.49 | ||
| Q2 25 | $-0.33 | $1.28 | ||
| Q1 25 | $-0.74 | $1.05 | ||
| Q4 24 | $-0.30 | $0.21 | ||
| Q3 24 | $-0.46 | $0.29 | ||
| Q2 24 | $-0.30 | $1.47 | ||
| Q1 24 | $-0.54 | $1.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $24.5M |
| 总债务越低越好 | — | $171.3M |
| 股东权益账面价值 | $370.1M | $379.2M |
| 总资产 | $1.1B | $800.4M |
| 负债/权益比越低杠杆越低 | — | 0.45× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $24.5M | ||
| Q3 25 | $479.2M | $22.7M | ||
| Q2 25 | $370.0M | $33.8M | ||
| Q1 25 | $358.4M | $16.2M | ||
| Q4 24 | $411.3M | $57.3M | ||
| Q3 24 | $396.9M | $33.6M | ||
| Q2 24 | $360.1M | $35.0M | ||
| Q1 24 | $325.9M | $43.7M |
| Q4 25 | — | $171.3M | ||
| Q3 25 | — | $154.7M | ||
| Q2 25 | — | $190.1M | ||
| Q1 25 | — | $189.5M | ||
| Q4 24 | — | $124.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $379.2M | ||
| Q3 25 | $401.2M | $423.1M | ||
| Q2 25 | $156.3M | $432.1M | ||
| Q1 25 | $164.2M | $419.9M | ||
| Q4 24 | $228.5M | $436.1M | ||
| Q3 24 | $237.1M | $444.5M | ||
| Q2 24 | $264.3M | $441.5M | ||
| Q1 24 | $266.7M | $408.9M |
| Q4 25 | $1.1B | $800.4M | ||
| Q3 25 | $1.1B | $816.3M | ||
| Q2 25 | $821.4M | $874.7M | ||
| Q1 25 | $807.3M | $852.8M | ||
| Q4 24 | $885.1M | $841.6M | ||
| Q3 24 | $901.9M | $843.6M | ||
| Q2 24 | $904.5M | $882.9M | ||
| Q1 24 | $831.9M | $867.8M |
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.37× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $59.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $47.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 27.8% |
| 资本支出强度资本支出/营收 | 0.1% | 6.9% |
| 现金转化率经营现金流/净利润 | — | 9.65× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $107.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $59.8M | ||
| Q3 25 | $108.5M | $74.4M | ||
| Q2 25 | $4.4M | $68.4M | ||
| Q1 25 | $-53.4M | $-37.7M | ||
| Q4 24 | $19.4M | $56.4M | ||
| Q3 24 | $34.1M | $86.4M | ||
| Q2 24 | $-8.3M | $56.2M | ||
| Q1 24 | $-133.0M | $-27.9M |
| Q4 25 | $-14.3M | $47.9M | ||
| Q3 25 | $108.3M | $59.2M | ||
| Q2 25 | $4.4M | $51.7M | ||
| Q1 25 | $-53.4M | $-51.0M | ||
| Q4 24 | $19.3M | $41.3M | ||
| Q3 24 | — | $67.3M | ||
| Q2 24 | $-8.4M | $36.8M | ||
| Q1 24 | $-133.3M | $-40.2M |
| Q4 25 | -7.1% | 27.8% | ||
| Q3 25 | 23.6% | 33.8% | ||
| Q2 25 | 2.5% | 23.7% | ||
| Q1 25 | -32.0% | -25.4% | ||
| Q4 24 | 9.1% | 26.4% | ||
| Q3 24 | — | 37.5% | ||
| Q2 24 | -4.2% | 15.2% | ||
| Q1 24 | -77.3% | -19.8% |
| Q4 25 | 0.1% | 6.9% | ||
| Q3 25 | 0.0% | 8.7% | ||
| Q2 25 | 0.0% | 7.7% | ||
| Q1 25 | 0.0% | 6.6% | ||
| Q4 24 | 0.0% | 9.7% | ||
| Q3 24 | 0.0% | 10.6% | ||
| Q2 24 | 0.0% | 8.0% | ||
| Q1 24 | 0.2% | 6.0% |
| Q4 25 | — | 9.65× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 1.89× | ||
| Q1 25 | — | -1.22× | ||
| Q4 24 | — | 8.95× | ||
| Q3 24 | — | 9.93× | ||
| Q2 24 | — | 1.27× | ||
| Q1 24 | — | -0.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
DFIN
| Technology Service | $68.0M | 39% |
| Capital Markets Compliance And Communications Management | $61.6M | 36% |
| Investment Companies Software Solutions | $30.9M | 18% |
| Print And Distribution Service | $13.6M | 8% |
